FIELD: medicine; pharmacology.
SUBSTANCE: invention claims method of forming a mass containing a) 50 to 99.4 wt % of at least one cross-linked non-thermoplastic carrier selected out of group including cross-linked polyvinylpyrrolidone and cross-linked sodium carboxycellulose, b) 0.5 to 30 wt % of at least one adjuvant selected out of group including thermoplastic polymers, lipids, polyatomic alcohols forming monosaccharide by oxidation, derivatives of polyatomic alcohols forming monosaccharide by oxidation, and solubilisators, and c) 0.1 to 49.5 wt % of bioactive substance with 1 mg/ml solubility in water at 25°C; at temperature of adjuvant softening or higher, at least 70°C, then the mass is cooled down. Measured forms are rapidly dissipating in water medium.
EFFECT: fast-releasing measured forms for low-soluble bioactive substances without the use of organic solvents or bioactive substance melting.
8 cl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL DOSED FORM, CONTAINING POLYMER CARRIER COMPOSITION | 2009 |
|
RU2519679C9 |
| PHARMACEUTICAL DRUG FORM OF TYROSINE KINASE INHIBITOR FOR PERORAL INTRODUCTION | 2007 |
|
RU2468788C2 |
| PHARMACEUTICAL COMPOSITION FOR HIV INFECTION TREATMENT | 2016 |
|
RU2619840C1 |
| PERORAL SOLID DOSAGE FORM WITH MYCOPHENOLIC ACID OR ITS SALT FOR USE AS AN IMMUNODEPRESSANT FOR TREATMENT OR PREVENTION OF ORGAN OR TISSUE TRANSPLANT REJECTION AND METHOD FOR PRODUCTION THEREOF | 2016 |
|
RU2670447C2 |
| PHARMACEUTICAL DOSED FORM FOR PERORAL INTRODUCTION OF BCL-2 FAMILY INHIBITOR | 2010 |
|
RU2568599C2 |
| COMPOSITION AND DOSAGE FORM CONTAINING SOLID OR SEMISOLID MATRIX | 2006 |
|
RU2423997C9 |
| PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF BCL-2 FAMILY INHIBITOR | 2010 |
|
RU2711359C2 |
| FOOD TONER | 2007 |
|
RU2438354C2 |
| HEPARIN-BASE FORMULATION | 2001 |
|
RU2278658C2 |
| PHARMACEUTICALLY ACCEPTABLE SOLUBILISING COMPOSITION AND PHARMACEUTICAL DOSAGE FORM CONTAINING IT | 2007 |
|
RU2469708C2 |
